Methicillin-Resistant Staphylococcus Aureus drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

  • ID: 4538141
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
1 of 4

FEATURED COMPANIES

  • Allergan
  • Basilea Pharmaceutica
  • Baxter International
  • Debiopharm Group
  • Melinta Therapeutics
  • Merck
  • MORE
The report on global methicillin-resistant staphylococcus aureus drugs market provides qualitative and quantitative analysis for the period of 2016 to 2024. The report predicts the global methicillin-resistant staphylococcus aureus drugs market to grow with a CAGR of 2.5% over the forecast period of 2018-2024. The study on methicillin-resistant staphylococcus aureus drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2016 to 2024.

The report on methicillin-resistant staphylococcus aureus drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global methicillin-resistant staphylococcus aureus drugs market over the period of 2016 to 2024. Moreover, the report is collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global methicillin-resistant staphylococcus aureus drugs market over the period of 2016 to 2024. Further, the Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Research Methodology

Primary Research

Primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached through:

1. Key Opinion Leaders associated
2. Internal and External subject matter experts
3. Professionals and participants from LinkedIn, Hoovers, Factiva and Bloggers

Primary research respondents typically include:

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include:

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Websites and publications by research agencies
5. Databases such as WTO, OECD, World Bank, and among others.

Segment Covered

The global methicillin-resistant staphylococcus aureus drugs market is segmented on the basis of drug class, MOA and drug origin.

Global Methicillin-resistant Staphylococcus Aureus drugs Market by Drug Class
  • Cephalosporin
  • Lipopeptides
  • Lipoglycopeptide
  • Folate Antagonist
  • Tetracycline
  • Oxazolidinone
Global Methicillin-resistant Staphylococcus Aureus drugs Market by MOA
  • Bactericidal Drugs
  • Bacteriostatic
Global Methicillin-resistant Staphylococcus Aureus drugs Market by Drug Origin
  • Synthetic Drugs
  • Semisynthetic
Company Profiles
  • Theravance Biopharma
  • Basilea Pharmaceutica
  • Pfizer
  • Debiopharm Group
  • Merck
  • Allergan
  • Melinta Therapeutics
  • AmpliPhi Biosciences Corporation
  • KYORIN Pharmaceutical Co. Ltd.
  • Baxter International
How this report delivers?

1. Comprehensive analysis of global as well as regional markets of methicillin-resistant staphylococcus aureus drugs market.

2. Complete coverage of all the segments in methicillin-resistant staphylococcus aureus drugs market to analyze the trends, developments in the global market and forecast of market size up to 2024.

3. Comprehensive analysis of the companies operating in global methicillin-resistant staphylococcus aureus drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. Growth Matrix presents analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • Basilea Pharmaceutica
  • Baxter International
  • Debiopharm Group
  • Melinta Therapeutics
  • Merck
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary

3. Global Methicillin-resistant Staphylococcus Aureus Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.5. Competitive Landscape in the Global Methicillin-resistant Staphylococcus Aureus Drugs Market

4. Global Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Class
4.1. Cephalosporin
4.2. Lipopeptides
4.3. Lipoglycopeptide
4.4. Folate Antagonist
4.5. Tetracycline
4.6. Oxazolidinone

5. Global Methicillin-resistant Staphylococcus Aureus Drugs Market by MOA
5.1. Bactericidal Drugs
5.2. Bacteriostatic

6. Global Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Origin
6.1. Synthetic Drugs
6.2. Semisynthetic

7. Global Methicillin-resistant Staphylococcus Aureus Drugs Market by Region 2018-2024
7.1. North America
7.1.1. North America Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Class
7.1.2. North America Methicillin-resistant Staphylococcus Aureus Drugs Market by MOA
7.1.3. North America Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Origin
7.1.4. North America Methicillin-resistant Staphylococcus Aureus Drugs Market by Country
7.2. Europe
7.2.1. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Class
7.2.2. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market by MOA
7.2.3. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Origin
7.2.4. Europe Methicillin-resistant Staphylococcus Aureus Drugs Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Class
7.3.2. Asia-Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market by MOA
7.3.3. Asia-Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Origin
7.3.4. Asia-Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market by Country
7.4. RoW
7.4.1. RoW Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Class
7.4.2. RoW Methicillin-resistant Staphylococcus Aureus Drugs Market by MOA
7.4.3. RoW Methicillin-resistant Staphylococcus Aureus Drugs Market by Drug Origin
7.4.4. RoW Methicillin-resistant Staphylococcus Aureus Drugs Market by Sub-region

8. Company Covered
8.1. Theravance Biopharma
8.2. Basilea Pharmaceutica
8.3. Pfizer
8.4. Debiopharm Group
8.5. Merck
8.6. Allergan
8.7. Melinta Therapeutics
8.8. Ampliphi Biosciences Corporation
8.9. Kyorin Pharmaceutical Co. Ltd.
8.10. Baxter International
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Theravance Biopharma
  • Basilea Pharmaceutica
  • Pfizer
  • Debiopharm Group
  • Merck
  • Allergan
  • Melinta Therapeutics
  • AmpliPhi Biosciences Corporation
  • KYORIN Pharmaceutical Co. Ltd.
  • Baxter International
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll